Avid Bioservices Inc (CDMO)

[sulaco]

JamesGMS, I've always appreciated your posts, but you're wrong

Today's Ronin PR was very significant.
The PPS jumped today for (2) reasons:

1) Ronin revealed its knowledge that the anti-PS platform is actually VERY VERY valuable.
2) BOD candidates such as Mr. Egan are unlikely to agree to front for an antibody "placebo."

To wit:

We believe Mr. Egan's deep understanding of antibodies, history of senior operations roles at reputable companies in the biotech industry, and proven ability to execute large deals with major pharmaceutical firms make him ideally suited for the Board...

Why mention his "deep understanding of antibodies"? I thought the IP was worthless. No, Ronin is sending a message. Anti-PS antibodies deserve VETERAN big-league attention.

James J. Egan ("Jamie") currently serves as a strategic advisor to Numab AG, a Swiss biotech company that develops antibody-based therapeutics.

Egan is working on Mabs NOW. He advises on "strategy." He will advise PPHM on "strategy." Why?

From 2001 – 2006, Jamie was Senior VP of Licensing and Corporate Development for biopharmaceutical company Idenix Pharmaceuticals, Inc. ("Idenix"), where he played an instrumental role in Novartis AG's $255 million investment in the company as part of a strategic alliance that allowed Idenix to go public in 2004. Idenix was later acquired by Merck & Co. in 2014 for nearly $3.9 billion.

JamesGMS, you and I have talked about buyout potential with Gilead, Roche, Merck, et. al. Sometimes, such buyouts come in steps, not all at once. Ronin and big-league BOD'ers can attract the investment that preps the anti-PS platform for acquisition. In case you misplaced your calculator, a similar (too low?) $3.9 billion buyout would kick the PPS to $86.67.

Mr. Egan has also held senior operations roles at pharmaceutical company G.D. Searle & Co. and global healthcare company Abbott Laboratories in the 1980's and 1990's.

Our current BOD has nothing even close to this experience. This EGAN guy has a ROLODEX.

Prior to becoming a biotech executive, Mr. Egan was a foreign services officer at the US embassy in Tokyo and an attorney with the Department of Justice. Mr. Egan is fluent in Japanese.

Okaaaayyy....
________________________________________________________________

JamesGMS, the PPS jumped today because a main-line Biotech veteran said, "Yes, that position interests me. I'm in." THAT sends a serious message. A disturbance in The Force, if you will. I guarantee Wall Street stopped sipping its coffee for a moment, and looked over its outstretched WSJ.

Today a significant shift occurred. Why, oh why, would a big-league insider want to join PPHM?

We all know PPHM has nothing. Or do they?


Best Regards friend,

Joe Six-Pack